An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer |
| |
Authors: | Casey M. Cosgrove David L. Tritchler David E. Cohn David G. Mutch Craig M. Rush Heather A. Lankes William T. Creasman David S. Miller Nilsa C. Ramirez Melissa A. Geller Matthew A. Powell Floor J. Backes Lisa M. Landrum Cynthia Timmers Adrian A. Suarez Richard J. Zaino Michael L. Pearl Paul A. DiSilvestro Paul J. Goodfellow |
| |
Affiliation: | 1. The Ohio State University, Columbus, OH, United States;2. NRG Oncology Statistics and Data Management Center, Buffalo, NY, United States;3. Washington University School of Medicine, St. Louis, MO, United States;4. Gynecologic Oncology Group Tissue Bank, Biopathology Center, Research Institute at Nationwide Children''s Hospital, Columbus, OH, United States;5. Department of Obstetrics & Gynecology, Medical University of South Carolina, Charleston, SC, United States;6. Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, United States;g. University of Minnesota, Minneapolis, MN, United States;h. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States;i. Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA, United States;j. Stony Brook University Hospital, Stony Brook, NY, United States;k. Women and Infants Hospital of Rhode Island, Providence, RI, United States;l. Roswell Park Cancer Institute, Buffalo, NY, United States |
| |
Abstract: | ObjectivesThe purpose of this study was to assess the prognostic significance of a simplified, clinically accessible classification system for endometrioid endometrial cancers combining Lynch syndrome screening and molecular risk stratification.MethodsTumors from NRG/GOG GOG210 were evaluated for mismatch repair defects (MSI, MMR IHC, and MLH1 methylation), POLE mutations, and loss of heterozygosity. TP53 was evaluated in a subset of cases. Tumors were assigned to four molecular classes. Relationships between molecular classes and clinicopathologic variables were assessed using contingency tests and Cox proportional methods.ResultsMolecular classification was successful for 982 tumors. Based on the NCI consensus MSI panel assessing MSI and loss of heterozygosity combined with POLE testing, 49% of tumors were classified copy number stable (CNS), 39% MMR deficient, 8% copy number altered (CNA) and 4% POLE mutant. Cancer-specific mortality occurred in 5% of patients with CNS tumors; 2.6% with POLE tumors; 7.6% with MMR deficient tumors and 19% with CNA tumors. The CNA group had worse progression-free (HR 2.31, 95%CI 1.53–3.49) and cancer-specific survival (HR 3.95; 95%CI 2.10–7.44). The POLE group had improved outcomes, but the differences were not statistically significant. CNA class remained significant for cancer-specific survival (HR 2.11; 95%CI 1.04–4.26) in multivariable analysis. The CNA molecular class was associated with TP53 mutation and expression status.ConclusionsA simple molecular classification for endometrioid endometrial cancers that can be easily combined with Lynch syndrome screening provides important prognostic information. These findings support prospective clinical validation and further studies on the predictive value of a simplified molecular classification system. |
| |
Keywords: | Endometrioid endometrial cancer Molecular classification Prognosis Combined Lynch syndrome screening and molecular classification |
本文献已被 ScienceDirect 等数据库收录! |
|